immunotherapy
People whose work centres on immunotherapy. 76 records carry it: 76 people.
Related tags
76 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Adrian Ochsenbein Director UCI; Chief Physician, Medical Oncology · Inselspital, Bern University Hospital / University Cancer Center Inselspital Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling. | Acute myeloid leukaemia, Chronic myeloid leukaemia | none | leadership, clinician-scientist, leukaemia | ||
Alexander J. Stratigos Professor of Dermatology, National and Kapodistrian University of Athens, Andreas Sygros Hospital · National and Kapodistrian University of Athens, School of Medicine Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines. | Locally advanced and metastatic basal cell carcinoma, Advanced cutaneous squamous cell carcinoma, Skin cancer | none | skin, guidelines | ||
Alfredo Addeo Head of Division, Oncology · Geneva University Hospitals (HUG) Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals. | Non-small-cell lung cancer, Small-cell lung cancer, Mesothelioma | none | leadership, clinician-scientist, lung cancer | ||
Alice P. Chen Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute · National Cancer Institute (NIH) NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer. | Alveolar soft part sarcoma, Sarcomas | none | sarcoma, rare-cancers, trialist | ||
Ana Oaknin Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona · Vall d'Hebron University Hospital / VHIO Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers. | Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Cervical cancer | none | endometrial, gynaecological, trialist | ||
Ann-Lii Cheng Distinguished Professor and Director, National Taiwan University Cancer Center · National Taiwan University Hospital Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer. | Hepatocellular carcinoma | none | hcc, asia | ||
Anna K. Nowak Professor of Medical Oncology and Dean of Medicine, University of Western Australia · University of Western Australia Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma. | Mesothelioma | none | mesothelioma, australia | ||
Antonio Rosato Scientific Director · Istituto Oncologico Veneto IRCCS Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research. | Melanoma | none | leadership, clinician-scientist | ||
Arjun V. Balar Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center · Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer. | Bladder & urothelial cancer | none | urothelial | ||
Barbara Burtness Professor of Medicine and Co-Leader, Developmental Therapeutics, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital Led KEYNOTE-048, which made pembrolizumab first-line therapy for recurrent or metastatic head and neck cancer. | Head and neck squamous cell carcinoma | none | head-and-neck, ecog-acrin | ||
Brian I. Rini Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research · Vanderbilt-Ingram Cancer Center Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer. | Renal cell carcinoma | none | rcc, trialist | ||
Bruno Sangro Translational Research lead, Executive Committee · Cancer Center Clínica Universidad de Navarra / CIMA Hepatologist at Clínica Universidad de Navarra and a leading international investigator in liver cancer systemic therapy and radioembolisation. | Hepatocellular carcinoma, Biliary tract cancer | none | clinician-scientist, liver cancer | ||
Caroline Robert Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University · Gustave Roussy Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma. | Melanoma | none | melanoma, trialist | ||
Danny Rischin Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma. | Advanced cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Skin cancer | none | skin, head-and-neck, trialist | ||
Dean A. Fennell Professor of Thoracic Medical Oncology, University of Leicester · Leicester Cancer Research Centre / University Hospitals of Leicester Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not. | Mesothelioma | none | mesothelioma, surgery, uk | ||
Dean F. Bajorin Attending Physician, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery. | Bladder & urothelial cancer | none | urothelial, adjuvant | ||
Dirk Schadendorf Director WTZ Essen; Director, Department of Dermatology · West German Cancer Center (WTZ), University Hospital Essen Melanoma expert who directs the West German Cancer Center at University Hospital Essen. | Melanoma, Cutaneous squamous cell carcinoma, Merkel cell carcinoma | none | leadership, clinician-scientist, melanoma | ||
Domenica Lorusso Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan · IRCCS Humanitas Research Hospital Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer. | Cervical cancer, Endometrial cancer, Ovarian cancer | none | cervical, italy | ||
Elias Jabbour Professor of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL. | Acute lymphoblastic leukaemia | none | all, chemo-free | ||
Elizabeth A. Mittendorf Director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center · Dana-Farber Brigham Cancer Center Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy. | Triple-negative breast cancer | none | tnbc, surgery | ||
Ezra E. W. Cohen Professor of Medicine and Chief of Hematology-Oncology, UC San Diego Moores Cancer Center · UC San Diego Moores Cancer Center Led KEYNOTE-040, which showed pembrolizumab improves survival in previously treated head and neck cancer. | Head and neck squamous cell carcinoma, Thyroid cancer | none | head-and-neck | ||
Gordon J. Freeman Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School · Dana-Farber Brigham Cancer Center Showed that PD-L1 is the ligand for PD-1 and that the pair switches T cells off, the foundation of checkpoint immunotherapy. | none | none | discovery, pd-1 | ||
Heinz-Josef Lenz Professor of Medicine and Co-Director, Colorectal Center, USC Norris Comprehensive Cancer Center · USC Norris Comprehensive Cancer Center Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease. | Colorectal cancer | none | colorectal, swog | ||
Howard L. Kaufman Surgical Oncologist, Massachusetts General Hospital; Chief Medical Officer, Ankyra Therapeutics · Massachusetts General Hospital Cancer Center Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy. | Melanoma, Merkel cell carcinoma | none | oncolytic-virus, melanoma | ||
Ignacio Melero Professor of Immunology, Universidad de Navarra; Senior Consultant, Clínica Universidad de Navarra · Cancer Center Clínica Universidad de Navarra / CIMA Spanish immunologist who pioneered CD137 agonist antibodies and intratumoural immunotherapy. | Hepatocellular carcinoma | none | costimulation, spain | ||
Inge M. van der Sluis Paediatric oncologist, Princess Máxima Center for Pediatric Oncology · Princess Máxima Center for Pediatric Oncology Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia. | Infant acute lymphoblastic leukaemia, Acute lymphoblastic leukaemia, Childhood cancers | none | paediatric, leukaemia, trialist | ||
Jaffer A. Ajani Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | gastric, esophageal | ||
Jean-Jacques Grob Professor of Dermatology, Aix-Marseille University, Hôpital de la Timone · Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials. | Advanced cutaneous squamous cell carcinoma, Melanoma, Skin cancer | none | skin, melanoma, trialist | ||
Jean-Pascal Machiels Head of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels · King Albert II Cancer Institute, Cliniques universitaires Saint-Luc Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer. | HPV-negative head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma | none | head-and-neck, trialist | ||
Jedd D. Wolchok Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine · Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive. | Melanoma | none | melanoma, trialist | ||
Jeffrey A. Bluestone Founding President and Chief Executive Officer, Parker Institute for Cancer Immunotherapy (2016 to 2021); Chief Executive Officer and President, Sonoma BioTherapeutics · Parker Institute for Cancer Immunotherapy The immunologist who ran the Parker Institute from its launch in 2016, building a shared research network across leading US cancer centres; he came from UCSF and now leads a regulatory T cell company. | none | none | leadership | ||
Joaquim Bellmunt Director, Bladder Cancer Center, Dana-Farber Cancer Institute; Associate Professor, Harvard Medical School · Dana-Farber Brigham Cancer Center Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer. | Bladder & urothelial cancer | none | urothelial | ||
John Stagg Director of the Rosalind and Morris Goodman Cancer Institute · Rosalind and Morris Goodman Cancer Institute, McGill University Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal. | none | none | leadership, clinician-scientist | ||
Jonathan E. Rosenberg Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer. | Bladder & urothelial cancer | none | urothelial, adc | ||
Jong-Mu Sun Medical oncologist, Samsung Medical Center, Seoul · Samsung Medical Center Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer. | Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Oesophageal cancer | none | oesophageal, trialist | ||
Jürgen Kuball Daily Board member, Strategic Program Cancer · UMC Utrecht Cancer Center Utrecht haematologist and immunotherapy researcher on the daily board of UMC Utrecht's cancer programme, known for gamma-delta T cell receptor-engineered cell therapies. | Acute myeloid leukaemia, Multiple myeloma | none | leadership, clinician-scientist, haematology | ||
Karen E. Knudsen Chief Executive Officer and Board Member, Parker Institute for Cancer Immunotherapy · Parker Institute for Cancer Immunotherapy The cancer biologist and former American Cancer Society chief executive who now runs the Parker Institute for Cancer Immunotherapy. | Prostate cancer | none | leadership | ||
Karim Vermaelen Chairperson, CRIG Steering Committee (2026-2028) · Ghent University Hospital / Cancer Research Institute Ghent Thoracic oncologist and tumour immunologist who chairs the Cancer Research Institute Ghent at Ghent University / UZ Gent. | Non-small-cell lung cancer, Mesothelioma | none | leadership, clinician-scientist, lung cancer | ||
Ken Kato Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo · National Cancer Center Hospital Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer. | Oesophageal cancer, Head and neck squamous cell carcinoma | none | esophageal, japan | ||
Kunle Odunsi Director · University of Chicago Medicine Comprehensive Cancer Center Gynaecologic oncologist and immunotherapy researcher who directs the University of Chicago Medicine Comprehensive Cancer Center. | Ovarian cancer | none | leadership, clinician-scientist, ovarian cancer | ||
Lieping Chen United Technologies Corporation Professor in Cancer Research, Yale School of Medicine · Yale School of Medicine / Yale Cancer Center Discovered PD-L1 (B7-H1) and showed tumours use it to escape immunity, the biology behind every anti-PD-1 drug. | none | none | discovery, pd-l1 | ||
Luis Paz-Ares Head of the H12O-CNIO Lung Cancer Clinical Research Unit · Hospital Universitario 12 de Octubre Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer. | Non-small-cell lung cancer, Small-cell lung cancer | none | clinician-scientist, lung cancer | ||
Marco Herold Chief Executive Officer, Olivia Newton-John Cancer Research Institute · Olivia Newton-John Cancer Wellness and Research Centre Cancer biologist who leads the Olivia Newton-John Cancer Research Institute, the research arm of the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne. | none | none | leadership, clinician-scientist, genome-editing | ||
Martin Reck Head of Thoracic Oncology, LungenClinic Grosshansdorf · LungenClinic Grosshansdorf Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer. | Non-small-cell lung cancer, Small-cell lung cancer | none | lung, trialist | ||
Matthew D. Hellmann Medical oncologist and trial lead, thoracic immunotherapy Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone. | PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer, Lung cancer | none | lung, trialist | ||
Michael A. Postow Chief, Melanoma Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects. | Melanoma | none | melanoma, toxicity | ||
Michael B. Atkins Deputy Director, Georgetown Lombardi Comprehensive Cancer Center · Georgetown Lombardi Comprehensive Cancer Center Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after. | Advanced melanoma, BRAF V600-mutant melanoma, Melanoma | none | melanoma, trialist | ||
Michael R. Migden Dermatologist and Mohs surgeon, MD Anderson Cancer Center · MD Anderson Cancer Center Houston dermatologist who led the trials that established cemiplimab, the first drug approved for advanced cutaneous squamous-cell carcinoma, and sonidegib for basal cell carcinoma. | Advanced cutaneous squamous cell carcinoma, Locally advanced and metastatic basal cell carcinoma, Skin cancer | none | skin, trialist | ||
Nai-Kong V. Cheung Enid A. Haupt Chair in Pediatric Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma. | Neuroblastoma | none | paediatric, neuroblastoma | ||
Neil D. Gross Head and neck surgeon, MD Anderson Cancer Center · MD Anderson Cancer Center Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations. | Advanced cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Skin cancer | none | skin, surgery, trialist | ||
Nicoletta Colombo Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca · IEO (European Institute of Oncology) Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer. | Cervical cancer, Ovarian cancer | none | cervical, guidelines | ||
Paolo A. Ascierto Director, Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples · Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial. | Melanoma | none | melanoma, italy | ||
Paul Baas Thoracic Oncologist, Netherlands Cancer Institute; Professor, University of Amsterdam · Netherlands Cancer Institute (NKI-AvL) Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years. | Mesothelioma | none | mesothelioma | ||
Peter Johnson Professor of Medical Oncology · University Hospital Southampton / Centre for Cancer Immunology Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer. | Hodgkin lymphoma, Diffuse large B-cell lymphoma | none | clinician-scientist, lymphoma | ||
Peter Schmid Professor of Cancer Medicine and Lead, Centre for Experimental Cancer Medicine, Barts Cancer Institute · Barts Cancer Institute / Barts Health NHS Trust Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer. | Triple-negative breast cancer | none | tnbc, trialist | ||
Philippe Armand Lymphoma specialist, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma. | Primary mediastinal (thymic) large B-cell lymphoma, Non-Hodgkin lymphoma | none | lymphoma, trialist | ||
Quincy Chu Medical oncologist, Cross Cancer Institute and University of Alberta, Edmonton · Cancer Care Alberta (Alberta Health Services) Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma. | Pleural mesothelioma | none | mesothelioma, trialist | ||
Ralf Gutzmer Dermato-oncologist and trial lead German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma. | BRAF V600-mutant melanoma, Melanoma | none | melanoma, trialist | ||
Ralph Weichselbaum Executive Committee Member · University of Chicago Medicine Comprehensive Cancer Center Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity. | none | none | clinician-scientist, radiotherapy | ||
Ramez N. Eskander Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center · UC San Diego Moores Cancer Center Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease. | Endometrial cancer | none | endometrial, nrg-oncology |
(showing the first 60)
The table above loads 60 of 76 records first and fetches the rest as you scroll, search or filter. This tag as JSON · table rows · API